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E-mail address: Haoquandoctor_2011@yahoo.cn (QThe mechanisms underlying ovarian cancer cell resistance to cisplatin (CDDP) are not fully under-
stood. MicroRNAs (miRNAs) play important roles in tumorigenesis and drug resistance. In this paper,
we utilized microRNA array and real-time PCR to show that miR-93 is signiﬁcantly up-regulated in
cisplatin-resistant ovarian cancer cells. In vitro assays show that over-expression and knock-down
of miR-93 regulate apoptotic activity, and thereby cisplatin chemosensitivity, in ovarian cells. Fur-
thermore, we found that miR-93 can directly target PTEN, and participates in the regulation of
the AKT signaling pathway. MiR-93 inversely correlates with PTEN expression in CDDP-resistant
and sensitive human ovarian cancer tissues. These results may have implications for therapeutic
strategies aiming to overcome ovarian cancer cell resistance to cisplatin.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Ovarian cancer is the leading cause of death from gynecologic
malignancies and the fourth most common cause of death due to
cancer among women. The regular treatment for ovarian cancer
is surgical intervention followed by combination chemotherapy
[1]. The main clinical obstacle is that the initial response rate is
poor, and most of the patients will experience disease recurrence.
Cisplatin is one of the most effective cell cycle non-speciﬁc drugs
for the treatment of ovarian cancer and the mechanism involved
in the process of its cytotoxicity include survival inhibition and
apoptosis [2]. The poor ﬁve-year survival rates in ovarian cancer
are partly due to the development of platinum resistance [3]. Until
now, CDDP chemoresistance still remains a major obstacle for the
successful treatment of ovarian cancer.
The characteristics of chemoresistance in cancer cells are linked
to mutational events (genetic hypothesis) and to non-mutational
alterations of gene function (epigenetic hypothesis). Although
focusing on known genes has already yielded new information,
previously unknown noncoding RNAs, such as microRNAs (miR-
NAs), may also lead insight into the biology of chemoresistancechemical Societies. Published by E
logy Cancer, Tianjin Medical
a. Fax: +86 22 23521569.
. Hao).[4]. MiRNAs, which are approximately 22 nt in length, are shown
to function as post-transcriptional regulators by binding to com-
plementary sites in the 30untranslated regions (30UTRs) of the tar-
get mRNAs [5]. Due to the wide range of target genes, miRNAs are
involved in various physiological and pathological processes,
including CDDP chemoresistance. Some miRNAs were found to
be up- or down-regulated in cancer cells characteristic of a CDDP
resistant phenotype, such as germ cell tumors [6], tongue
squamous cell carcinoma [7] and MCF-7 breast cancer cells [8].
Up-regulation of miR-451 increases CDDP sensitivity of non-small
cell lung cancer cell line A549 [9], and miR-148a could sensitize
esophageal cancer cell lines to CDDP [10]. On the contrary, miR-
141 could counteract the CDDP-induced apoptosis in esophageal
squamous cell carcinoma by targeting YAP1 [11]. MiR-200c
induces CDDP chemoresistance in esophageal cancers through
interacting with the AKT signaling pathway [12]. Moreover, miR-
214 could enhance ovarian cancer cell survival and induce CDDP
resistance primarily through targeting the PTEN/AKT pathway
[13]. These studies together highlight the need to study miRNAs
that are involved in CDDP chemoresistance in various cancers.
However, whether there are other unknown miRNAs that are
involved in the function and mechanism of CDDP chemosensitivity
in ovarian cancer is still largely unknown.
In the present study, we induced CDDP-resistant OVCAR3 and
SKOV3 human ovarian cancer cells, and then detected thelsevier B.V. All rights reserved.
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the parent cancer cells. MiR-93 was found to be up-regulated in
both of the two CDDP-resistant ovarian cancer cell lines, and the
tumor suppressor gene phosphatase and tensin homolog (PTEN)
was conﬁrmed to be a direct target gene of miR-93. Overexpression
of miR-93 could suppress PTEN expression and induce CDDP
chemoresistance in parent OVCAR3 and SKOV3 cells, which could
be partly alleviated by ectopic expression of PTEN. Conversely, sup-
pression of miR-93 led to the increase of PTEN expression and
CDDP sensitization in CDDP-resistant OVCAR3 and SKOV3 cells,
which was partly alleviated by PTEN siRNA. Furthermore, miR-93
mediated suppression of PTEN could induce phosphorylation of
AKT1, which was indicated to facilitate cell survival and reduction
of apoptosis. Taken together, miR-93 plays a critical role in
regulating CDDP chemosensitivity through suppression of PTEN
expression, and it may serve as a potential target for overcoming
CDDP resistance in human ovarian cancer.2. Materials and methods
2.1. Ovarian cancer tissue samples, cell culture, transfection and RNA
extraction
The CDDP-sensitive and -resistant ovarian cancer tissue
samples were obtained from Tianjin Medical University Cancer
Hospital with patients’ informed consent. All the samples were
snap-frozen in liquid nitrogen and stored at 80 C until use.
Human ovarian cancer cell line OVCAR3 and SKOV3 were
maintained in RPMI-1640 (Invitrogen) supplemented with 10%
fetal bovine serum (FBS), 100 IU/ml of penicillin, 100 lg/ml of
streptomycin, and variant concentration of CDDP (Wako) if needed.
Cells were cultured at 37 C in a humidiﬁed atmosphere containing
5% CO2. Transfection was performed using Lipofectamine 2000 Re-
agent (Invitrogen) following the manufacturer’s instructions. RNA
extraction was performed using mirVana™ miRNA Isolation Kit
(Ambion) according to the manufacturer’s protocol.
2.2. Induction of CDDP-resistant ovarian cancer cell lines
The CDDP-resistant ovarian cancer cell lines were induced using
progressive concentration of CDDP. Brieﬂy, the OVCAR3 and SKOV3
cells in logarithmic growth were treated with 0.5 lmol/L of CDDP.
After 48h, CDDP was withdrawn and cells were cultured without
CDDP until they recovered. Then, the same treatment was per-
formed, and when the cells were resistant to the current concen-
tration, the CDDP concentration was gradually increased to 1, 2,
3, 4 and ﬁnally to 6 lmol/L. When the induced cells survived in
6 lmol/L of CDDP for about 2 months with a normal activity, and
withdrawn of CDDP, they still keep the same activity and CDDP
resistance characteristic with the condition of 6 lmol/L CDDP
drugs in the culture medium, the cells were conﬁrmed to be
CDDP-resistant and named OVCAR3/CDDP and SKOV3/CDDP.
2.3. IC50 analysis
Cytotoxicity of CDDP was measured using 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The loga-
rithmically growing ovarian cancer cells were plated in 96-well
plates with 0, 20, 40, 60, 80, or 100 lmol/L of CDDP. At 48 h after
CDDP treatment, MTT was added into cells to a ﬁnal concentration
of 0.5 mg/ml. Four hours later, the reduced insoluble MTT was re-
moved and the formazan was solubilized in 100 ml dimethyl sulf-
oxide. The absorbance of each well was determined at 490 nm
using a lQuant Universal Microplate Spectrophotometer (Bio-Tech
Instruments, Winooski, USA). The concentration of CDDP thatcaused 50% inhibition of ovarian cancer cell activity were deﬁned
as IC50.
2.4. MiRNA microarray
The miRNA microarray analysis was performed as previously
described [14]. Brieﬂy, 30 lg of puriﬁed small RNA was fraction-
ated on urea denaturing 15% polyacrylamide gel, and 18–26 nt of
RNAs were recovered and puriﬁed. Two oligonucleotide adaptors
were then ligated to the 50 and 30 ends of the retrieved RNA using
T4 RNA ligase (Fermentas). A cDNA library was generated by re-
verse transcription using M-MLV reverse transcriptase (Promega)
and the product was ampliﬁed using asymmetric PCR and labeled
with Cy3 or Cy5. The samples were hybridized to the microarray
containing 640 human mature miRNA probes at 42 C overnight
Then the slide was washed and scanned. The miRNAs displayed
up- or down-regulation for more than threefold was picked out
to be the dysregulated miRNAs.
2.5. Quantitative RT-PCR
For the detection of miR-93 level, the stem-loop quantitative RT-
PCR [15] was performed. SYBR Premix Ex TaqTM Kit (TaKaRa) was
used following the manufacturer’s instructions, and the real-time
PCR was performed and analyzed by iQ5 Real-Time PCR Detection
System (Bio-Rad). PCR cycles were as follows: 95 C for 3 min,
followed by 40 cycles of 95 C for 30 s, 56 C for 30 s, 72 C for 30 s.
2.6. Bioinformatics
The target genes of miRNA were predicted by the following two
computer-aided algorithms: TargetScan Release 5.2 (http://www.
targetscan.org) and PicTar (http://pictar.mdc-berlin.de/cgi-bin/
new_PicTar_vertebrate.cgi).
2.7. EGFP reporter assay
To conﬁrm the direct interaction of miRNA and the target mRNA,
the ovarian cancer cells were plated in 48-well plates and transfec-
ted with the EGFP reporter vectors along with the miR-93 expres-
sion vector or the miR-93 blockage (20-O-methyl miR-93 ASO,
50-cuaccugcacgaacagcacuuug-30). An accordant amount of red
ﬂuorescence protein (RFP) expression vector pDsRed2-N1 was co-
transfected into each group to be used for normalization. At 48 h
post-transfection, cells were lyzed with ratio immunoprecipitation
assay lysis buffer (RIPA lysis buffer, 50 mM Tris–HCl pH 7.2,
150 mM NaCl, 1% Triton X–100, 0.1% SDS) and total proteins were
harvested. The intensity of EGFP and RFP ﬂuorescence were de-
tected with a Fluorescence Spectrophotometer F-4500 (HITACHI).
2.8. Western blot
At 72 h after transfection, the ovarian cancer cells were lyzed
with RIPA lysis buffer and proteins were harvested. The protein
of tissue samples were extracted using TRIzol Reagent (Invitrogen).
Proteins were resolved on an SDS denatured polyacrylamide gel
and then transferred onto a nitrocellulose membrane. Antibodies
to PTEN, AKT1, phosphorylated AKT1 or the endogenous control
GAPDHwere incubated with the blot overnight at 4 C. Membranes
were washed and incubated with horseradish peroxidase (HRP)
conjugated secondary antibody. Protein expression was assessed
by enhanced chemiluminescence and exposure to chemilumines-
cent ﬁlm. LabWorks™ Image Acquisition and Analysis Software
(UVP) was used to quantify band intensities. The antibodies were
purchased from Saier (Tianjin, China).
Fig. 1. miR-93 is up-regulated in CDDP-resistant ovarian cancer cell lines. (A) Gradually increased CDDP was added into OVCAR3 and SKOV3 cells to induce the CDDP-
resistant ovarian cancer cell lines. The sensitivity of the induced cells to CDDP was measured using MTT assay, and the IC50 was calculated as described in the Section
’Materials and methods’ part. (B) The miR-93 expression level in the ﬁnally induced CDDP-resistant cells was measured using quantitative RT-PCR assay. U6 snRNA was
regarded as the endogenous normalizer and the relative miR-93 expression level is shown (⁄p < 0.05).
Table 1
Dysregulated miRNAs in OVCAR3/CDDP and SKOV3/CDDP cells by miRNA
microarray.
miRNA ID Fold change
OVCAR3/CDDP: OVCAR3 SKOV3/CDDP: SKOV3
hsa-miR-15a 3.24 8.71
hsa-miR-19a 12.78 4.87
hsa-miR-21 3.57 7.62
hsa-miR-204 3.16 5.59
hsa-miR-93 9.47 7.28
hsa-miR-96 4.74 6.21
hsa-miR-22 0.19 0.22
hsa-miR-489 0.27 0.16
The fold change of dysregulated miRNAs in CDDP-resistant ovarian cancer
cells compared to the parent cells is shown.
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Enumeration of apoptotic cells was done by using FITC conju-
gated Annexin V (BD Pharmingen, San Jose, CA) and 7-aminoacti-
nomycin D (7-AAD). Cells were washed twice in cold 1 PBS and
resuspended in Annexin V–binding buffer (BD Pharmingen) at a
concentration of 3  106 per ml. This suspension (100 ll) wasFig. 2. PTEN is a direct target gene of miR-93. (A) As is predicted in TargetScan database
PTEN 30UTR is also shown. (B) EGFP reporter assay was performed in the parental and
vector with wild-type or mutated PTEN 30UTR fragment, along with the miR-93 ectopic
accordant amount of RFP expression vector pDsRed2-N1 was co-transfected into each gr
the intensity of EGFP and RFP ﬂuorescence was detected. The normalized EGFP intensitstained with 5 ll of Annexin V-FITC and 5 ll 7-AAD. 7-AAD (BD
Pharmingen) is a nucleic acid dye and used for exclusion of nonvi-
able cells. These cells were gently vortexed and incubated for
15 min at room temperature in the dark. After addition of 400 ll
of binding buffer to each tube, cells were analyzed by ﬂow
cytometry.
2.10. Statistical analysis
All the experiments were carried out in triplicate and data were
analyzed using SPSS v11.0. Quantitative values were expressed as
means ± SD, and statistical analysis utilized two-tailed Student’s t
test. Statistical signiﬁcance was set as p < 0.05.
3. Results
3.1. The expression level of miR-93 was up-regulated in CDDP-
resistant ovarian cancer cell lines OVCAR3/CDDP and SKOV3/CDDP
To seek the miRNAs associated with CDDP resistance in ovarian
cancer cells, we ﬁrst established the CDDP-resistant OVCAR3/CDDP
and SKOV3/CDDP cells by progressive concentration of CDDP from
0.5 lmol/L to 6 lmol/L. Using MTT assay, we found that the IC50 of, the PTEN 30UTR carries a potential miR-93 binding site. The sequence of mutated
CDDP-resistant OVCAR3 and SKOV3 cells. Cells were transfected with the reporter
expression vector (pcDNA3/pri-miR-93) or the miR-93 blockage (miR-93 ASO). An
oup to be used for normalization. At 48 h post transfection the cells were lysed and
y is shown (⁄p < 0.05).
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times, respectively, compared with the parent cancer cells
(Fig. 1A). Next, we used miRNA microarray analysis to screen the
dysregulated miRNAs in the ovarian cancer cell lines. As a result,
six miRNAs were showed signiﬁcantly up-regulation, and two miR-
NAs were showed signiﬁcantly down-regulation in both the OV-
CAR3/CDDP and SKOV3/CDDP cells (Table 1). The microarray
datas were veriﬁed by the quantitative RT-PCR assay, in which
miR-93 showed completely coincidence trend with the microarray
(Fig. 1B). Thus, we chose miR-93 as a potential regulator in the pro-
cess of ovarian cancer cell chemosensitivity adjustment to CDDP in
the further study.Fig. 3. MiR-93 regulate cisplatin chemosensitivity in OVCAR3 and SKOV3 cells by targe
vector (pcDNA3/pri-miR-93) with or without a PTEN ectopic expression vector (PTEN),
protein level in the transfected OVCAR3 and SKOV3 cells was measured using Western b
the relative PTEN protein level. (C) The sensitivity of the transfected cells to CDDP w
transfected with miR-93 blockage (miR-93 ASO) with or without a PTEN siRNA express
(⁄p < 0.05).3.2. MiR-93 directly targets PTEN 30UTR and negatively regulates its
expression
The cellular functions of miRNAs are revealed through their tar-
get genes. With the help of PicTar-Vert and Target Scan databases,
we hypothesized PTEN, a tumor suppressor gene with phosphory-
lase activity, to be a potential target gene of miR-93, and found the
target site of miR-93within the PTEN 30UTR (Fig. 2A). Next, we used
EGFP reporter assay to conﬁrm the direct regulation of PTENbymiR-
93 in the parent and CDDP-resistant ovarian cancer cell lines. When
the EGFP reporter vector with the wild type PTEN 30UTR was used,
overexpression of miR-93 in the parent OVCAR3 and SKOV3 cellsting PTEN. (A) OVCAR3 and SKOV3 cells were transfected with miR-93 expression
and the miR-93 level was detected using quantitative RT-PCR assay. (B) The PTEN
lot assay. GAPDH was used as the endogenous normalizer, and the histogram shows
as measured using IC50 index. (D-F) OVCAR3/CDDP and SKOV3/CDDP cells were
ion vector (si-PTEN), and the same experiments as described above was performed
Fig. 4. miR-93 exhibits opposite alteration to PTEN in CDDP-resistant human ovarian cancer tissues. Five CDDP-resistant and ﬁve CDDP-sensitive human ovarian cancer
tissues were collected, and the expression of miR-93 and PTEN was detected at the mRNA and protein levels by quantitative RT-PCR assay (A) and Western blot assay (B),
respectively (⁄p < 0.05).
Fig. 5. Suppression of PTEN expression by miR-93 could induce phosphorylation of
AKT1. Parental OVCAR3 and SKOV3 cells were transfected with the miR-93 ectopic
expression vector (pcDNA3/pri-miR-93) with or without a PTEN ectopic expression
vector (PTEN). Then, the levels of phosphorylated AKT1 and total AKT1 were
measured using Western blot assay. LY-294002 is a potent inhibitor of phospho-
inositide 3-kinases (PI3Ks), which served here as a reference of the dephosphoryl-
ated AKT1 (⁄p < 0.05).
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CDDP-resistant OVCAR3/CDDP and SKOV3/CDDP cells led to an in-
crease of EGFP expression (Fig. 2B and C). The binding was speciﬁc,
because the EGFP reporter vector with themutated PTEN 30UTRwas
not affected by the change ofmiR-93 (Fig. 2B and C). These data indi-
cated that PTEN is directly and negatively regulated by miR-93.
3.3. MiR-93 could regulate cisplatin chemosensitivity in OVCAR3 and
SKOV3 cells by targeting PTEN
Given that miR-93a showed a high expression level in CDDP-
resistant ovarian cancer cells, we explored that if miR-93a maycontribute to the CDDP chemoresistance in ovarian cancer. We
used the pcDNA3 vector to express miR-93 and PTEN cDNA coding
sequence without 30UTR. The miR-93 was over-expressed in the
parent OVCAR3 and SKOV3 cells when transfected with pri-miR-
93 but without subject to the effects of PTEN expression
(Fig. 3A). Over expression of miR-93 could suppress the PTEN pro-
tein expression level, which could be partly restored by the ectopic
PTEN expression vector because of the effect of the miR-93 regula-
tory site (Fig. 3B). In the cellular activity assays, we found that ec-
topic expression of miR-93 could enhance the CDDP resistance in
parent OVCAR3 and SKOV3 cells. Furthermore, when PTEN was ec-
topic expressed, the miR-93 enhanced chemoresistance was partly
alleviated (Fig. 3C). On the other hand, miR-93 antisense oligonu-
cleotides (ASO) were used to suppress miR-93 activity, and PTEN
small interfering RNA (siRNA) technology to inhibit PTEN expres-
sion in CDDP-resistant OVCAR3 and SKOV3 cells (Fig. 3D). As is
presumed, suppression of miR-93 could lead to increase of PTEN
expression level and enhance the CDDP chemosensitivity, both of
which could be partly alleviated by the PTEN siRNA (Fig. 3E and
F). We also compared the miR-93 and PTEN expression level in
clinical fresh ovarian cancer tissue samples with different chemo-
sensitivity to CDDP determined by in vitro drug resistance assay
[16]. MiR-93 was showed about 2.5-fold higher expression level
(Fig. 4A), while PTEN was showed about 0.22-fold lower level
(Fig. 4B) in CDDP-resistant ovarian cancer tissues compared with
CDDP-sensitive ovarian cancer tissues. We concluded that miR-
93 may regulate CDDP chemosensitivity in ovarian cancer cells
by directly targeting PTEN.
3.4. Suppression of PTEN expression by miR-93 could induce
phosphorylation of AKT1
AKT is one of the major cell survival pathway molecules and its
activation form phospho-Akt plays a key role in multiple drug
resistance, including cisplatin [17,18], so we measured the total
AKT1 and phosphorylated AKT1 expression level in the transfected
ovarian cancer cells. In both the OVCAR3 and SKOV3 cells, over-
expression of miR-93 could increase the ratio of the phosphory-
lated AKT1/total AKT, and this could be partly alleviated by the
PTEN expression vector (Fig. 5). This result showed that miR-93
can regulate PTEN/AKT1 signaling pathway through directly tar-
geting PTEN.
3.5. MiR-93 regulates anti-apoptosis activity by targeting PTEN in both
resistant- and sensitive ovarian cancer cells
To demonstrate that if the effect of miR-93 in regulating cis-
platin chemosensitivity is via reduction of apoptosis activity in
Fig. 6. miR-93 regulates anti-apoptosis activity by targeting PTEN in both resistant and sensitive colon cancer cells. (A and B) OVCAR3 and SKOV3 cells were transfected with
different oligos and plasmids. 48 h after the treatment, cells were labeled with Annexin V and analyzed by ﬂow cytometry. The representive images show that the apoptotic
rate was reduced by transfection with miR-93 minics and rescued with PTEN expression vectors. Three independent experiments were done with two breast cancer cell lines
in each group. (C and D) The similar treatment was done in OCVAR3/CDDP and SKOV3/CDDP cells and then FACS assays was performed the same way as (A and B).
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groups of transfected ovarian cancer cells. As shown in Fig. 6, in
sensitive ovarian cancer cells OVCAR3 and SKOV3, the apoptotic
rates were reduced by about 60% and 48%, respectively in miR-93
mimics group compared with the Oilgo NC group and almost res-
cued by 33% and 43% by PTEN expression (Fig. 6A). The similar re-
sult was obtained in resistant ovarian cancer cells OVCAR3/CDDP
and SKOV3/CDDP treated with miR-93 ASO, PTEN siRNA and con-
trol oligos (Fig. 6B). These results suggest that miR-93 may play
an important role in regulating cisplatin chemosensitivity directly
through adjustment of anti-apoptosis activity by targeting PTEN in
ovarian cancer cells.
4. Discussion
MiRNAs are a class of small, noncoding RNAs, about 22 nt in
length, which regulate gene expression by targeting mRNAs for
translational repression, mRNA degradation or both. Recently, a lar-
ger number of miRNAs that were deregulated in different types of
human malignancy were identiﬁed [19–21]. These miRNAs play
an important regulatory role in pathogenesis of tumor in human in-
volved in cell proliferation, differentiation, apoptosis, metastasis,
and drug resistance [22–25]. Thus far, there are several published
miRNAs that were reported to involved in the process of cisplantin
resistance in varies tumors include miR-451, miR-21, miR-214,
miR-23a and miR-141 [7,11,13]. Base on these ﬁndings, we
performed global miRNA expression proﬁling in human ovarian cis-
platin-resistance andparental cancer cells to ﬁnd that up-regulationof miR-15a, miR-19a, miR-21, miR-204, miR-93, miR-96 and
down-regulation of miR-22, miR-489 are recurrent events. This
ﬁndings suggest that dysregulation of these miRNAs may represent
CDDP-induced ones without any chemosensitivity adjustment
function or have some certain contribution to regulate cisplatin
chemosensitivity in ovarian cancer.
MiR-93 is over-expressed with the similar folds in the cis-
platin-resistant OVCR3/CDDP and SKOV3/CDDP cells compared
with its corresponding cisplatin-sensitive parental cell lines (Table
1), and subsequent real-time PCR experiment conﬁrmed this result
(Fig. 1). Knockdown of miR-93 enhance cisplatin chemosensitivity
in cisplatin-resistant OVCR3/CDDP and SKOV3/CDDP cells, while
ectopic expression of miR-93 renders OVCR3 and SKOV3 cells more
resistant to cisplatin-induced apoptosis. It has been well reported
that constitutive activation of AKT contributes to chemoresistance
in different types of tumors, including ovarian carcinoma [17].
Recent studies have demonstrated BIM as a key regulator partici-
pating in the AKT pathway in Cisplatin-sensitive and -resistant
ovarian cancer cells [26]. Yang et al. have reported that miR-214
induces cisplatin resistance by targeting PTEN [13]. In our study,
we conﬁrmed that miR-93, a new family member of PTEN
regulator, blocks PTEN translation leading to activation of the
AKT pathway and played an important role in regulating cisplatin
chemosensitivity pathway in ovarian cancer.
MiR-93, a typical member of miR-106b-25 clusters, is partici-
pating in many kinds of cellular biological processes. One report
showed that miR-93 affects the proliferation and survival of
HTLV-1-infected/transformed cells through target TP53INP1 [27],
Fig. 7. Schematic representation showing the sequence of steps by which, miR-93,
a new family member of PTEN regulator, regulates PTEN and phospho-Akt
expression, anti-apoptosis activity and ﬁnally regulates CDDP chemo-sensitivity.
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bers directly target TGF-b receptor II to enhance iPSC generation
[28]. In hyperglycemic conditions, miR-93 could participate in
VEGF signaling pathway and down-regulate the expression of
VEGF-A in the progression of diabetic nephropathy [29]. To the
best of our knowledge, however, the deﬁnitive effect of miR-93
on other anti-cancer drugs chemosensitivity such as docetaxel,
paclitaxel, and doxorubicin/adriamycin has not been reported, only
given the evidences showing that the miR-93 is dysregulated in
drug-resistant cell lines in microRNA expression proﬁling study.
A typical example is that miR-93 is down-regulated in doxorubicin
resistant cell lines MCF/ADR [30,31]. In another study gives an con-
troversial results that, although following the same concentration
of oxaliplatin (the derivatives of cisplatin), evaluation of miR-93
was found to be up-regulated 3 times in HCT-116 colon cancer cell
line, while down-regulated by 50% in another colon cancer cell line
HCT-8 [32].
Although the classic PTEN pathway illustrates that PTEN can de-
crease the AKT activity through dephosphorylate PIP3 [33–35], the
upstream regulators of PTEN were not fully understood. Previous
studies show that some miRNAs such as miR-19a/b, miR-29a,
miR-214, miR-205 and miR-494, can directly regulate the expres-
sion of PTEN in a post-transcription regulation manner, through
interacting with its three-untranslated region in various cell lines
[36–40]. In the present study, we showed that PTEN is negatively
regulated by miR-93 at the protein level and the expression levels
of PTEN negatively correlates with miR-93 in both the ovarian
cancer cell lines OVCR3, SKOV3 and freshly surgical removed
ovarian cancer specimens. The cisplatin-resistant ovarian cancer
specimens showed a relative higher expression of miR-93, and
lower PTEN expression compared with cisplatin-sensitive ones
(Fig. 4). Therefore, these data indicate that miR-93 could be a
new member of the miRNAs that was the upstream regulator of
PTEN, which was involved in AKT signal pathway through targeting
PTEN. But it is not clear whether and how these conﬁrmed miRNAs
such as miR-214, miR-494, miR-205 directly targeting PTEN
co-regulate the PTEN/Akt pathway, further inﬂuences the CDDP
drug resistance and other biological function in a collaborative or
antagonistic manner (Fig. 7).
In conclusion, we have shown that miR-93 has a modulator
effect on PTEN expression and its downstream AKT signal pathway,
anti-apoptosis activity, which play important roles in regulating
cisplatin chemosensitivity in ovarian cancer. These results provide
a strong rationale for the development of miRNA-based therapeuticstrategies aiming to overcome ovarian cancer cell CDDP resistance.
Further studies are under way to characterize if miR-93 can regu-
late other anti-cancer drug chemosensitivity, serve as prognostic
and/or diagnostic markers as well as its in vivo role in ovarian tu-
mor cisplatin resistance by creating nude mice model.
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